Spero.jpg
Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense
January 13, 2020 08:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR720 and Announces Plans to Advance Program into Proof-of-Concept Clinical Trial in Patients with NTM Pulmonary Disease
December 04, 2019 16:01 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 29, 2019 15:45 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 29, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics to Host Key Opinion Leader Symposium in December
November 26, 2019 08:30 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces Third Quarter 2019 Operating Results and Provides Pipeline Review
November 04, 2019 16:05 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 31, 2019 17:08 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces Positive Recommendation to Continue Phase 3 Clinical Trial of SPR994 as Planned Following Independent Review Committee Analysis of SPR994 Treated Patients in Lead-in Cohort of Trial
October 03, 2019 08:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2019 17:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces Presentations at IDWeek 2019
September 26, 2019 08:30 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces Second Quarter 2019 Operating Results and Provides Pipeline Update
August 08, 2019 16:10 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...